Morgan Stanley increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 360,113 shares of the medical equipment provider’s stock after buying an additional 130,992 shares during the period. Morgan Stanley owned approximately 0.98% of Lantheus Holdings worth $4,502,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Trexquant Investment LP bought a new position in shares of Lantheus Holdings during the first quarter worth about $332,000. Nordea Investment Management AB raised its position in shares of Lantheus Holdings by 23.7% in the first quarter. Nordea Investment Management AB now owns 127,700 shares of the medical equipment provider’s stock worth $1,596,000 after buying an additional 24,500 shares during the last quarter. Systematic Financial Management LP bought a new position in shares of Lantheus Holdings during the first quarter worth about $1,314,000. Bank of New York Mellon Corp raised its position in shares of Lantheus Holdings by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares during the last quarter. Finally, LSV Asset Management raised its position in shares of Lantheus Holdings by 18.8% in the first quarter. LSV Asset Management now owns 182,700 shares of the medical equipment provider’s stock worth $2,283,000 after buying an additional 28,900 shares during the last quarter. Institutional investors and hedge funds own 66.32% of the company’s stock.
Shares of Lantheus Holdings, Inc. (LNTH) traded up 4.028% during mid-day trading on Friday, reaching $18.725. 57,380 shares of the company were exchanged. The stock has a 50 day moving average price of $17.92 and a 200-day moving average price of $14.14. The stock has a market capitalization of $699.38 million, a P/E ratio of 25.581 and a beta of 0.91. Lantheus Holdings, Inc. has a 12 month low of $5.68 and a 12 month high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.18. The company had revenue of $88.83 million for the quarter, compared to analysts’ expectations of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. Lantheus Holdings’s revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. Analysts predict that Lantheus Holdings, Inc. will post $1.07 earnings per share for the current year.
LNTH has been the topic of a number of recent analyst reports. Jefferies Group LLC restated a “buy” rating and set a $15.00 price target on shares of Lantheus Holdings in a research note on Wednesday, April 26th. Zacks Investment Research raised shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $17.00 price objective on the stock in a report on Thursday, May 4th. Credit Suisse Group upped their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald started coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.60.
In other Lantheus Holdings news, CEO Mary Anne Heino sold 10,000 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $15.39, for a total value of $153,900.00. Following the transaction, the chief executive officer now directly owns 602,468 shares of the company’s stock, valued at approximately $9,271,982.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael P. Duffy sold 20,000 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $15.42, for a total transaction of $308,400.00. Following the sale, the insider now owns 188,234 shares in the company, valued at $2,902,568.28. The disclosure for this sale can be found here. Insiders sold a total of 3,040,000 shares of company stock worth $45,252,800 over the last three months. 2.30% of the stock is currently owned by corporate insiders.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
What are top analysts saying about Lantheus Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lantheus Holdings Inc. and related companies.